Literature DB >> 17909619

New molecularly targeted therapies for lung cancer.

Sophie Sun1, Joan H Schiller, Monica Spinola, John D Minna.   

Abstract

Lung cancer is the leading cause of cancer death worldwide. The disease is particularly difficult to detect, and patients often present at an advanced stage. Current treatments have limited effectiveness, and unfortunately, the prognosis remains poor. Recent insights into the molecular pathogenesis and biologic behavior of lung cancer have led to the development of rationally designed methods of early detection, prevention, and treatment of this disease. This article will review the important clinical implications of these advances, with a focus on new molecularly targeted therapies currently in development.

Entities:  

Mesh:

Year:  2007        PMID: 17909619      PMCID: PMC1994616          DOI: 10.1172/JCI31809

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  121 in total

Review 1.  The Hedgehog and Wnt signalling pathways in cancer.

Authors:  J Taipale; P A Beachy
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  Developmental signalling pathways in lung cancer.

Authors:  Vincent C Daniel; Craig D Peacock; D Neil Watkins
Journal:  Respirology       Date:  2006-05       Impact factor: 6.424

Review 3.  Epithelial stem cells of the lung: privileged few or opportunities for many?

Authors:  Emma L Rawlins; Brigid L M Hogan
Journal:  Development       Date:  2006-05-30       Impact factor: 6.868

4.  PIK3CA mutation status in Japanese lung cancer patients.

Authors:  Osamu Kawano; Hidefumi Sasaki; Katsuhiko Endo; Eriko Suzuki; Hiroshi Haneda; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2006-08-22       Impact factor: 5.705

5.  Molecular and functional properties of lung SP cells.

Authors:  Susan D Reynolds; Hongmei Shen; Paul R Reynolds; Tomoko Betsuyaku; Joseph M Pilewski; Federica Gambelli; Michelangelo Di Giuseppe; Michelangelo DeGuiseppe; Luis A Ortiz; Barry R Stripp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-01       Impact factor: 5.464

6.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

7.  Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Authors:  Michael P Fanucchi; Frank V Fossella; Robert Belt; Ronald Natale; Panos Fidias; David P Carbone; Ramaswamy Govindan; Luis E Raez; Francisco Robert; Maria Ribeiro; Wallace Akerley; Karen Kelly; Steven A Limentani; Jeffrey Crawford; Hans-Joachim Reimers; Rita Axelrod; Oscar Kashala; Shihong Sheng; Joan H Schiller
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

9.  A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Authors:  Yan Lu; William Lemon; Peng-Yuan Liu; Yijun Yi; Carl Morrison; Ping Yang; Zhifu Sun; Janos Szoke; William L Gerald; Mark Watson; Ramaswamy Govindan; Ming You
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  88 in total

1.  MED19 promotes proliferation and tumorigenesis of lung cancer.

Authors:  Mei Sun; Rui Jiang; Jin-Dong Li; Shu-Li Luo; Hong-Wen Gao; Cheng-Yan Jin; Dong-Lei Shi; Chun-Guang Wang; Bin Wang; Xing-Yi Zhang
Journal:  Mol Cell Biochem       Date:  2011-04-26       Impact factor: 3.396

2.  Lung development and the host response to influenza A virus are altered by different doses of neonatal oxygen in mice.

Authors:  Bradley W Buczynski; Min Yee; B Paige Lawrence; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-03-09       Impact factor: 5.464

Review 3.  Signal control through Raf: in sickness and in health.

Authors:  Jihan K Osborne; Elma Zaganjor; Melanie H Cobb
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

4.  An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

Authors:  Amrita Basu; Nicole E Bodycombe; Jaime H Cheah; Edmund V Price; Ke Liu; Giannina I Schaefer; Richard Y Ebright; Michelle L Stewart; Daisuke Ito; Stephanie Wang; Abigail L Bracha; Ted Liefeld; Mathias Wawer; Joshua C Gilbert; Andrew J Wilson; Nicolas Stransky; Gregory V Kryukov; Vlado Dancik; Jordi Barretina; Levi A Garraway; C Suk-Yee Hon; Benito Munoz; Joshua A Bittker; Brent R Stockwell; Dineo Khabele; Andrew M Stern; Paul A Clemons; Alykhan F Shamji; Stuart L Schreiber
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

5.  Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro.

Authors:  Shuhong Hao; Xiaoyuan Du; Yang Song; Ming Ren; Qiwei Yang; Ao Wang; Qingyu Wang; Haiyue Zhao; Zhenwu Du; Guizhen Zhang
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 6.  Resident cellular components of the lung: developmental aspects.

Authors:  Wellington V Cardoso; Jeffrey A Whitsett
Journal:  Proc Am Thorac Soc       Date:  2008-09-15

Review 7.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

8.  Transformer 2β (Tra2β/SFRS10) positively regulates the progression of NSCLC via promoting cell proliferation.

Authors:  Lili Ji; Tingting Ni; Yanbo Shen; Qun Xue; Yifei Liu; Buyou Chen; Xuefan Cui; Liting Lv; Xiafei Yu; Yuan Cui; Xiaoning Lu; Jie Chen; Guoxin Mao; Yuchan Wang
Journal:  J Mol Histol       Date:  2014-06-21       Impact factor: 2.611

9.  AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Authors:  Hannah A Scarborough; Barbara A Helfrich; Matias Casás-Selves; Alwin G Schuller; Shaun E Grosskurth; Jihye Kim; Aik-Choon Tan; Daniel C Chan; Zhiyong Zhang; Vadym Zaberezhnyy; Paul A Bunn; James DeGregori
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

10.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.